142 results on '"Liwing, Johan"'
Search Results
2. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
3. Bridging the Gap Between RCTs and RWE Through Endpoint Selection
4. Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer—A Systematic Literature Review and Pooling of Individual Participant Data
5. 360 Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer
6. Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection
7. Cardiovascular, bone, and metabolic health in men with castrate-resistant prostate cancer treated with androgen deprivation: a matched cohort study
8. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
9. Comparison of Algorithms for Oral Busulphan Area Under the Concentration–Time Curve Limited Sampling Estimate
10. CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion
11. Real world treatment utilization patterns in patients with castration-resistant prostate cancer
12. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
13. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients
14. Real world treatment utilization patterns in patients with castration-resistant prostate cancer
15. Involved free light chain: an early independent predictor of response and progression in multiple myeloma
16. Sickness absence and concurrent low back and neck–shoulder pain: results from the MUSIC-Norrtälje study
17. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
18. A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis
19. Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
20. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
21. Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection
22. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
23. Bridging the Gap Between RCTs and RWE Through Endpoint Selection
24. PD10-06 REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
25. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden
26. Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data
27. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
28. Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway
29. Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.
30. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma.
31. Is a deep response the key to successful treatment of multiple myeloma?
32. Trial efficacy vs real world evidence effectiveness in first line treatment of multiple myeloma
33. Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data
34. Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
35. The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
36. Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care? : A Population Based Study Including 1542 Patients
37. Is Multiple Myeloma a Chronic Disease? : A Population Based Study Comparing 1843 Patients to a Matched Swedish Population
38. Follow-up of Real Life Treated Multiple Myeloma Patients : Response, Disease Progression and Overall Survival
39. Cost-effectiveness modelling of epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anaemia in Sweden
40. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
41. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
42. Comparison of Algorithms for Oral Busulphan Area Under the Concentration–Time Curve Limited Sampling Estimate
43. Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients
44. Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.
45. Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival,
46. Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach
47. HIGH COSTS FOR CO-OCCURRENCE OF NECK/SHOULDER AND LOW BACK DISORDERS IN SWEDEN
48. Sickness absence and concurrent low back and neck–shoulder pain: results from the MUSIC-Norrtälje study
49. Hypervelocity jets and homuncular motion in eta Carinae: an application of Fabry-Perot, ADONIS, and AO sofware.
50. ESO photometric and astrometric analysis program for AO: a programmatic and numerical analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.